LUMO News and Press, Lumos Pharma Inc. From 05/05/22

AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, initially targeting pediatric growth hormone deficiency, today announced a collaboration with Laura Dichtel, MD of Mass...

AUSTIN, Tex., April 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its first quarter 2022 financial results after market close on Tuesday, May 10, 2022. The company will host a conference call and...

- Interim Data Anticipated by End of 2022 - -   Interim Data from PK/PD OraGrowtH212 Trial also Anticipated by End of 2022 - AUSTIN, Texas, April 11, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company f...

AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that John McKew, PhD, President and Chief Scientific Officer of Lumos Pharma, will participate in a panel d...

The following slide deck was published by Lumos Pharma, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Lumos Pharma, Inc. 2021 Q4 - Results - Earnings Call Presentation

Lumos Pharma, Inc. (LUMO) Q4 2021 Earnings Conference Call March 10, 2022, 04:30 PM ET Company Participants Lisa Miller - Senior Director of Investor Relations Rick Hawkins - Chief Executive Officer & Chairman Lori Lawley - Chief Financial Officer & Principal Accounting Officer John M...

Lumos Pharma press release (NASDAQ:LUMO): FY GAAP EPS of -$3.65 beats by $0.24. Revenue of $0.23M (+35.3% Y/Y) beats by $0.22M. For further details see: Lumos Pharma GAAP EPS of -$3.65 beats by $0.24, revenue of $0.23M beats by $0.22M

AUSTIN, Texas, March 10, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the year ended December 31, 2021, announced plans to conduct interim analyses of its ...

AUSTIN, Texas, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its full year 2021 financial results after market close on Thursday, March 10, 2022. Th...

AUSTIN, Texas, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Conference being held January 10-13,...